Home/Pipeline/Glatiramer Acetate

Glatiramer Acetate

Multiple Sclerosis

CommercialActive

Key Facts

Indication

Multiple Sclerosis

Phase

Commercial

Status

Active

Company

Cipla

About Cipla

Founded in 1935, Cipla has established itself as a pioneering pharmaceutical company committed to improving global health outcomes through affordable medicines. The company operates across multiple therapeutic areas including respiratory, oncology, anti-retroviral, and complex generics, with a particular strength in inhalation products and biosimilars. Cipla's integrated business model spans from API manufacturing to finished formulations, with a growing focus on digital health solutions and specialty products for developed markets.

View full company profile

Therapeutic Areas

Respiratory Oncology HIV/AIDS Cardiology Neurology Dermatology Gastroenterology

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Zeposia (ozanimod)	Bristol Myers Squibb	Commercial	Approved
Copaxone (glatiramer acetate)	Teva Pharmaceutical Industries	Commercial	Marketed
Multiple Sclerosis Portfolio	Biogen	Commercial	Active
Kesimpta (ofatumumab)	Genmab	Approved	Commercial
Glatiramer Acetate (Generic Copaxone)	Dr. Reddy's Laboratories	Approved	Commercial
Interferon β-1a	Bachem	Commercial	Active collaboration with GlyTech
KYV-101	Kyverna Therapeutics	Phase 1/2	Active, recruiting
Azer-cel (PBCAR0191)	Precision BioSciences	Phase 1/2	Partnered with TG Therapeutics; Clinical milestone achieved
CYMS101	FibroBiologics	Pre-clinical / Limited Clinical	Active